Acupuncture For Acute Non-Specific Low Back Pain: A Pilot Randomised Non-Penetrating Sham Controlled Trial
Acupuncture For Acute Non-Specific Low Back Pain: A Pilot Randomised Non-Penetrating Sham Controlled Trial
Acupuncture For Acute Non-Specific Low Back Pain: A Pilot Randomised Non-Penetrating Sham Controlled Trial
available at www.sciencedirect.com
a
Health and Rehabilitation Sciences Research Institute, School of Health Sciences, University of Ulster,
Northern Ireland, United Kingdom
b
Centre for Physiotherapy Research, School of Physiotherapy, University of Otago, New Zealand
c
Division for Research and Education in Complementary and Integrative Medical Therapies, Harvard Medical School,
Osher Institute, USA
Available online 27 April 2007
KEYWORDS Summary
Acupuncture; Objective: A pilot study to assess the feasibility of a trial to investigate the efficacy of acupunc-
Acupuncture therapy; ture compared to placebo needling for the treatment of acute low back pain (LBP). As part of
Low back pain; this, the study was designed to establish the credibility of the placebo control, and to provide
Backache; data to inform a power analysis to determine numbers for a future trial.
Non-penetrating Study design: A pilot patient and assessor blinded randomized controlled trial.
sham control; Setting: Primary care health centre facility, South and East Belfast Trust, Northern Ireland.
Placebo; Patients: Patients from the physiotherapy waiting list (n = 48) with LBP of less than 12 weeks
Randomized duration.
controlled trial; Outcome measures: Roland and Morris Disability Questionnaire (RMDQ), Visual Analogue Scale
Blinding; (VAS), medication use and an exit questionnaire were completed at baseline, end of treatment,
Pilot study and at 3 months follow up.
Results: Ninety-four percent (45/48) of patients completed assigned treatment, 83% (40/48)
completed 3 months follow-up. The sham needle used here proved to be credible: 91.7% in
the placebo group believed they had received acupuncture, compared to 95.8% in the verum
acupuncture group. Differences in baseline characteristics were accounted for using ANCOVA.
There was no significant difference between groups on the RMDQ over time. For pain, the only
statistically significant difference was at the 3 months follow up (worst VAS, point estimate,
18.7, 95% CI 1.5—36.0, p = 0.034). The majority of patients were taking some form of analgesic
medication for LBP at the start of treatment (n = 44; 92%), and at the end of treatment the
verum acupuncture group were taking significantly fewer tablets of pain control medication
(mean (S.D.): 1.0 ± 0.3) than the placebo group (mean (S.D.): 4.2 ± 0.6, p < 0.05). Based upon
0965-2299/$ — see front matter © 2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ctim.2007.03.001
140 S. Kennedy et al.
these data, power analysis (power = 90%, alpha = 0.05, minimal clinically important difference
(MCID) for RMDQ = 2.5 points) indicated that 120 participants (60 per group) would be needed to
complete an adequately powered randomized controlled trial.
Conclusions: This study has demonstrated the feasibility of a randomized controlled trial of
penetrating needle acupuncture compared to a non-penetrating sham for the treatment of acute
LBP in primary care; 120 participants would be required in a fully powered trial. The placebo
needle used in this study proved to be a credible form of control.
© 2007 Elsevier Ltd. All rights reserved.
GV3 Below spinous process 4th lumbar vertebra Perpendicular 0.5—1 in.
GV4 Below spinous process 2nd lumbar vertebra Perpendicular 0.5—1 in.
BL23 1.5 cun lateral to lower border of spinous process 2nd Perpendicular 1—1.5 in.
lumbar vertebra
BL25 1.5 cun lateral to lower border of spinous process 4th Perpendicular 1—1.5 in.
lumbar vertebra, level with iliac crest
GB29 Midway between ASIS and greater trochanter Perpendicular 0.5—1 in.
GB30 Junction of middle and lateral third of the distance Perpendicular 2—3 in.
between great trochanter and sacral hiatus
GB31 Midline lat aspect thigh (tip of middle finger) Perpendicular 0.7—1.2 in.
GB34 In the depression anterior and inferior to fibula head Perpendicular 1—1.5 in.
BL36 Middle of transverse gluteal fold Perpendicular 0.7—1.5 in.
BL37 6 cun below BL36 Perpendicular 0.7—1.5 in.
BL40 Middle of transverse crease popliteal fossa Perpendicular 0.5—1.5 in.
BL56 Centre of belly of gastrocnemius Perpendicular 0.5—1.5 in.
BL60 Depression between lateral malleolus and TA Perpendicular 0.5 in.
was achieved, or for 30 s using an even technique. Nee- Outcome measures and follow-up procedures
dle retention time was 30 min per treatment. The Park
Sham Device (AcuPrime, UK) with verum acupuncture nee- A range of outcome measures were used as recom-
dles were used (Spring and Scarborough, Wujiang jia chen mended by Bombardier26 : these included questionnaires
Acupuncture Devices Co. Ltd.; sterile single use needles with proven psychometric properties for LBP-specific
with guide tube, size 0.25 mm × 40 mm) to maintain patient functional disability26—28 (Roland and Morris Disability Ques-
blinding. tionnaire, RMDQ) and pain29 (Visual Analogue Scale, VAS),
Control intervention. The same Park Sham Device and a multidimensional patient-centred questionnaire (work
(AcuPrime, UK) was also used in the control group, so absenteeism, analgesic medication consumption, additional
that patients were blinded to treatment5,7 ; however in healthcare). These were completed at baseline, discharge,
this group non-penetrating sham needles were used which and 3 months (by post). An exit questionnaire which assessed
touched but did not penetrate the skin (sterile single use patient satisfaction, success of blinding, and evaluated the
needles with guide tube, size 0.3 mm × 40 mm, AcuPrime, credibility of the placebo was also completed by each
Dong Bang Acupuncture Inc, Korea). The same acupuncture patient at the end of treatment.
points and clinical protocol was followed for the control
as for the verum acupuncture group to ensure the same
therapeutic experience. Data analyses
Co-interventions. Clinical guidelines recommend advice to
remain active and medication as routine care for acute All variables were analysed using the Statistical Package
LBP.13,24 Advice was standardised at the first treatment by for the Social Sciences (SPSS) version 11. Intention-to-treat
giving all participants the Back Book, an evidence-based analysis was carried out by an investigator who was masked
booklet, developed for use by patients with LBP.25 Medica- to treatment allocation. Any missing data were replaced
tion intake was not controlled and may have been prescribed by carrying forward the most recent non-missing value.
by the referring physician or obtained over the counter by Analysis of covariance (ANCOVA), using pretreatment value
the patient. Medication intake was recorded at initial assess- as the covariate, was used to determine any differences
ment and patients were asked to complete a daily diary between the groups at the post-treatment and follow-up
to record the type of medication, the dose in mg and the visits. Exploratory analysis was carried out using numbers
number taken per day. of treatments as an additional covariate, and the numbers
Blinding. Given the nature of the treatments, it was pos- of treatments between the groups was compared using the
sible to blind subjects but not therapists with respect to Mann—Whitney test. Analgesic intake between the groups
the content of the interventions. The success of patient was compared using the Van Elteren test, which is a modifi-
blinding was assessed at the end of treatment. The primary cation of the Mann—Whitney test that accounts for baseline
researcher, who was unaware of patient allocation until the differences.30 Because of doubts about the appropriateness
completion of the data analysis, carried out data collection of parametric ANCOVA for medication usage, the baseline
at all time points. medication usage was grouped into four categories using
Compliance and drop-outs. Non-compliance was defined quartile cut-points (category 1: 0—25% = 0—2 tablets, cat-
as receipt of less than three treatments, but such patients egory 2: 25—50% = 3—4 tablets, category 3: 50—75% = 5—8
were included in subsequent follow-ups for the purposes of tablets and category 4: 75—100% = 9—15 tablets). The result-
intention-to treat analysis. ing categories were used as baseline scores in a Van Elteren
142 S. Kennedy et al.
RMDQ 12.7 ± 1.1 6.0 ± 1.0 5.0 ± 1.0 12.8 ± 1.1 7.0 ± 1.3 7.7 ± 1.5
VAS average 56.2 ± 5.7 27.3 ± 4.9 26.5 ± 5.2 62.6 ± 4.0 36.3 ± 6.1 40.7 ± 6.2
VAS worst 76.4 ± 4.7 40.71 ± 6.1 33.3 ± 5.7 73.8 ± 4.1 52.5 ± 6.1 51.7 ± 5.8
Days off work 11.1 ± 4.5 13.9 ± 5.3 — 7.5 ± 2.3 10.9 ± 4.1 —
Medication intake (tablets per day) 4.2 ± 0.6 1.0 ± 0.3 — 5.3 ± 0.8 4.2 ± 0.6 —
The estimated marginal mean differences in all outcome group (4.2 ± 0.6). This difference remained significant after
measures at the end of treatment and follow up (adjusted allowance for pretreatment differences in medication usage
for baseline values) are summarized in Table 4. There was (p < 0.05, Van Elteren test).
no significant difference between groups on the RMDQ over Patients received a mean of 5.7 treatments. There was
time. a significant difference between groups in the number of
Pain was measured as average pain and worst pain. There treatments received (Mann—Whitney test, p = 0.001). The
was no significant difference between groups at the end of acupuncture group received more treatments (6.3 ± 1.5;
treatment for average pain or worst pain (p > 0.05); how- mean ± S.D.): 11 patients in this group received more than
ever, at follow up there was a trend towards a greater six treatments, compared to none in the placebo group
analgesic effect for average pain in the verum acupuncture (5.2 ± 1.4). In exploring the effect of this on each outcome
group (average VAS: estimated marginal mean difference measure there was only weak evidence (p = 0.075) for a posi-
from baseline, 10.6, 95% CI −0.41 to 25.3, p = 0.152). In the tive relationship between RMDQ at the follow-up period and
case of worst pain, such differences were found to be sta- the number of treatments received; however allowance for
tistically significant at the 3 months follow up (worst VAS: this by using the number of treatments as a covariate in the
estimated marginal mean difference from baseline, 18.7, analysis did not substantially affect the conclusions.
95% CI 1.5—36.0, p = 0.034).
Results for medication intake showed that the majority
of patients were taking some form of analgesic medica- Power analysis
tion for LBP at the start of treatment (n = 44; 92%). At
the end of treatment, subjects in the verum acupuncture The current data were used to calculate numbers required
group were taking significantly fewer doses (tablets per day) to detect significant differences for pain (average VAS) and
of medication (1.0 ± 0.3; mean ± S.E.M.) than the placebo RMDQ between groups. For average pain, using an estimated
Table 4 This table shows the estimated marginal mean values for verum and placebo acupuncture adjusted for the initial
baseline score for each outcome measure, and the between-group difference values plus statistical analyses of these values
RMDQ end of treatment 6.1 ± 1.0 7.0 ± 1.0 0.9 ± 1.4 0.504
95% CI, 5.0—8.9 95% CI, 4.1—8.0 95% CI, −1.8—3.7
3 months 5.1 ± 1.2 7.7 ± 1.2 2.6 ± 1.6 follow up 0.119
95% CI, 2.7—7.4 95% CI, 5.3—10.0 95% CI, −0.7—5.9
VAS average end of treatment 28.8 ± 5.2 34.9 ± 5.2 6.1 ± 7.4 0.12
95% CI, 18.3—39.2 95% CI, 24.4—45.3 95% CI, −8.7—20.9
3 months 28.3 ± 5.1 38.9 ± 5.1 10.6 ± 7.3 0.152
95% CI, 17.9—38.6 95% CI, 28.5—49.2 95% CI, −4.1—25.3
VAS worst end of treatment 40.4 ± 6.1 52.8 ± 6.1 12.5 ± 8.6 0.152
95% CI, 28.2—52.5 95% CI, 40.7—65.0 95% CI, −4.8—29.7
3 months 33.1 ± 6.1 51.8 ± 61 18.7 ± 8.6 0.034
95% CI, 20.8—45.3 95% CI, 39.6—64.0 95% CI, 1.5—36.0
Significant differences between groups are in bold for worst VAS, the acupuncture group demonstrated significant hypoalgesia at follow
up.
144 S. Kennedy et al.
treatment. No significant effects were observed for func- placebo-acupuncture for postoperative nausea and vomiting
tion, although there was a trend for a greater (clinically prophylaxis: a randomized placebo-controlled patient and
important) improvement in the verum group at follow up. observer blind trial. Anaesthesia 2004;59:142—9.
Previous studies have been unable to disentangle spe- 7. Park J, White AR, James MA, Hemsley AG, Johnson P, Cham-
cific from non-specific placebo effects, as all such trials bers J, et al. Acupuncture for sub-acute stroke rehabilitation: a
sham controlled, subject- and assessor-blind, randomised trial.
used penetrating needles23,35,36 which may produce physi-
Arch Intern Med 2005;165:2016—31.
ological effects.37,38 It was interesting the specific effect 8. Furlan AD, Van Tulder MW, Cherkin DC, Tsukayama H, Lao L,
shown here increased over time to its greatest values at Koes BW, et al. Acupuncture and dry-needling for low back
the 3 months follow up, and although difficult to interpret, pain. Cochrane Database Syst Rev 2005. Issue I.
similar ‘delayed’ analgesic effects have been observed in 9. Manheimer E, White A, Berman B, Forys K, Ernst E. Meta-
other studies23,39 at a 3 months and at 24 months follow up, analysis: acupuncture for low back pain. Ann Intern Med
respectively. 2005;142(8):651—63.
Treatment dose was not controlled in this trial, as we 10. Hulley SB, Cummings SR. Implementing the study design:
were interested in any differences in uptake of treatments pretesting, quality control and protocol revisions. In: Hulley SB,
between groups. Although patients in the verum group Cummings SR, Browner WS, et al., editors. Designing clinical
research. 2nd ed. Philadelphia: Lippincott Williams & Wilkins;
received more treatment than those in the sham group,
2001. p. 259—61.
when this was accounted for in the analysis, it did not change 11. Earl-Slater A. The handbook of clinical trials and other
results for pain or function. Whilst reasons for such differ- research. Oxon: Radcliffe Medical Press; 2002. p. 81—2.
ences are unclear, both therapists and patients could have 12. Van Tulder MW, Assendelft WJJ, Koes BW, Bouter LM. Method
influenced this; factors explaining these differences should guidelines for systematic reviews in the Cochrane Col-
be explored in future trials. laboration Back Review Group for spinal disorders. Spine
Apart from being underpowered, another limitation of 1997;22:2323—30.
the study was the record of medication intake: patients were 13. Clinical Standards Advisory Group Report on Back Pain. London:
asked to record in a daily diary the type of medication, Her Majesty’s Stationery Office; 1994. p. 1—89.
the dose in mg, and the number taken per day. However, 14. Dawson V. What do I get for my AACP membership subscription?
J Acupunct Assoc Chart Phys 2003;7:8.
compliance was poor and thus data were extracted from
15. Stux G, Berman B, Pomeranz B. Basics of acupuncture. 5th ed.
the therapists’ charts which indicated only the number of Springer; 2003.
tablets per day. In a future trial it would be more useful to 16. Chaitow L. The acupuncture treatment of pain. Healing Arts
record detailed medication intake prior to each treatment, Press; 1990.
or provide patients with a prompt for a daily entry (e.g. 17. Ellis N. Acupuncture in clinical practice. Chapman and Hall;
electronically). 1994.
In conclusion, this pilot has demonstrated the feasibility 18. Hopwood V, Lovesey M, Mokone S, Lewith G. Acupuncture and
of a randomized controlled trial in this area, using RMDQ as a related techniques in physical therapy. Churchill Livingstone;
primary outcome, and secondary outcomes of pain and med- 1997.
ication intake. Results of such a trial would address the lack 19. Stux G, Pomeranz B. Basics of acupuncture. 4th ed. Springer;
1997.
of high quality evidence for the specific effect of acupunc-
20. Ross J. Acupuncture point combinations. Churchill Livingstone;
ture in acute LBP, as highlighted by two recent systematic 1999.
reviews.8,9 21. Xinnong C. Chinese acupuncture and moxibustion. 2nd ed. Bei-
jing: 1997 Foreign Languages Press; 1999.
22. Carlsson CP, Sjolund BH. Acupuncture for chronic low back pain:
Disclosure a randomised placebo-controlled study with long-term follow-
up. Clin J Pain 2001;17:296—305.
Dr Park developed the Park Sham Device and supplied the 23. Molsberger AF, Mau J, Pawelec DB, Winkler J. Does acupuncture
samples for use in the study. improve the orthopedic management of chronic low back pain—
–a randomized, blinded, controlled trial with 3 months follow-
up. Pain 2002;99:579—87.
References 24. European Commission COST B13 Management Committee.
European Guidelines for the Management of Chronic Non-
1. Sherman K, Cherkin D. Challenges of acupuncture research: specific Low Back Pain; 2004.
study design considerations. Clin Acupunct Orient Med 25. Burton K, Roland M, Waddell G, Klaber Moffett J, Main C. The
2003;3:200—6. back book. The best way to deal with back pain. 2nd ed. The
2. Dincer F, Linde K. Sham interventions in randomised clinical tri- Stationary Office; 2002.
als of acupuncture, a review. Comp Ther Med 2003;11:235—42. 26. Bombardier C. Outcome assessments in the evaluation of treat-
3. Streitberger K, Kleinhenz J. Introducing a placebo needle into ment of spinal disorders. Spine 2000;25:3100—3.
acupuncture research. Lancet 1998;352:364—5. 27. Kopec JA. Measuring functional outcomes in persons with back
4. Kleinhenz J, Streitberger K, Windeler J, Gubbacher AB, pain. Spine 2000;25:3110—4.
Mavridis G, Martin E. Randomised clinical trial comparing the 28. Garratt AM, Klaber Moffett J, Farrin AJ. Responsiveness of
effects of acupuncture and a newly designed placebo needle generic and specific measures of health outcome in low back
in rotator cuff tendinitis. Pain 1999;83:235—41. pain. Spine 2001;26:71—7.
5. Park J, White AR, Stevinson C, Ernst E, James M. Validating 29. Scott J, Huskisson EG. Vertical or horizontal visual analogue
a new non-penetrating sham acupuncture device: two ran- scales. Ann Rhem Dis 1978;38:560.
domised controlled trials. Acupunct Med 2002;20:168—74. 30. Lehmann EL. Nonparametrics: statistical methods based
6. Streitberger K, Diefenbacher M, Bauer A, Conradi R, Bar- on ranks. San Francisco: Holden-Day; 1975. p. 132—7,
denheuer H, Martin E, et al. Acupuncture compared to 145.
146 S. Kennedy et al.
31. Roland M, Fairbanks J. The Roland Morris Disability Ques- pain—–a randomised, blinded, placebo-controlled trial with 9-
tionnaire and the Owestry Disability Questionnaire. Spine month follow-up. Pain 2002;96:189—96.
2000;25:3115—24. 36. Brinkhaus B, Witt CM, Jena S, Linde K, Streng A, Wagenpfeil S,
32. Moher D, Schulz KF, Altman DG. The CONSORT statement: et al. Acupuncture in patients with chronic low back pain. A
revised recommendations for improving the quality of reports randomized controlled trial. Arch Intern Med 2006;166:450—7.
of parallel-group randomised trials. Lancet 2001;357:1191—4. 37. Le Bars D, Dickenson AH, Besson JM. Diffuse noxious inhibitory
33. Beurskens AJHM, De Vet HCW, Koke AJA. Responsiveness of controls (DNIC). I. Effects on dorsal horn convergent neurones
functional status in low back pain: a comparison of different in the rat. Pain 1979;6(3):283—304.
instruments. Pain 1996;65:71—6. 38. Vincent C, Lewith G. Placebo controls for acupuncture studies.
34. Stratford PW, Blinkley JM, Riddle DL, Guyatt GH. Sensitivity to J Roy Soc Med 1995;88:199—202.
changes of the Roland Morris Back Pain Questionnaire, Part 1. 39. Thomas KJ, MacPherson H, Ratcliff J, Thorpe L, Brazier J,
Phys Ther 1998;78:1186—96. Campbell M, et al. Longer term clinical and economic bene-
35. Leibing E, Leonhardt U, Koster G, Goerlitz A, Rosenfeldt JA, fits of offering acupuncture care to patients with chronic low
Hilgers R, et al. Acupuncture treatment of chronic low-back back pain. Health Tech Assess 2005;9(32).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.